Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide

Annals of Hematology

Volumn 94, Issue 4, 2015, Pages 643-649

  Lau, I Jun ^a   Smith, Dean ^b   Aitchison, Robin ^c   Blesing, Norbert ^d   Roberts, Pamela ^a   Peniket, Andrew ^a   Yong, Kwee ^b   Rabin, Neil ^b   Ramasamy, Karthik ^a,e,f  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c BUCKINGHAMSHIRE HEALTHCARE NHS TRUST   (United Kingdom)

^d GREAT WESTERN HOSPITAL   (United Kingdom)

^e ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^f NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

Bendamustine; Dexamethasone; Myeloma; Relapsed refractory; Thalidomide

Indexed keywords

ALANINE AMINOTRANSFERASE; BENDAMUSTINE; BORTEZOMIB; CREATININE; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CHLORMETHINE DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DEHYDRATION; FEMALE; FOLLOW UP; FRACTURE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PROCEDURES; RECURRENT DISEASE; SURVIVAL; TREATMENT FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT FAILURE;

EID: 84925497833     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2238-2     Document Type: Article

References (30)

1. Kumar SK, Rajikumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520
2. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajikumar SV, Durie BGM, on behalf of the International Myeloma Working Group (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukaemia 26:149–157
3. Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, Reece D, Stewart KA, Trieu Y, Trudel S, Chen CI (2013) D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol 161:802–810
4. Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D’Sa S, Rabin N, Johnston R, Schey S, Yong K (2013) Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. Eur J Haematol 90:420–425
5. Petrucci MT, Levi A, Bringhen S, Scotti S, Gentilini F, Russo S, Siniscalchi A, Larocca A, Grammatico S, Boccadoro M, Foà R, Palumbo A (2013) Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study. Cancer 119:971–977
6. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foá R, Hellmann A, Dimopoulos M, Swern AS, Knight R (2012) Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. Int J Hematol 96:254–262
7. Ozegowski W, Krebs D. (1971) IMET 3393, gamma-(1-methyl-5-bis-(ß-chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste. Zbl Pharm. 110:1013–19
8. Leoni LM, Bailey B, Reifert J (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309–317
9. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R (2008) Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 134(2):245–253
10. Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G (2007) Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 48:2345–2351
11. Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z (2014) Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123(7):985–991
12. Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz H-J, Schmalfeld M, Assmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, Al Ali H, Niederweiser D (2012) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139:499–508
13. Grey-Davies E, Bosworth JL, Boyd KD, Ebdon C, Saso R, Chitnavis D, Mercieca JE, Morgan GJ, Davies FE (2012) Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 156:552–555
14. Pratt G, Bowcock S, Lai M, Bell S, Bird J, D’Sa S, Cavenagh J, Cook G, Morgan G, Owen R, Snowden JA, Yong K, Davies F, on behalf of the United Kingdom Myeloma Forum (2013) United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. Int J Lab Hematol. [Epub ahead of print]
15. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D (2013) Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160:321–330
16. Pönisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Röhrborn R, Hebenstreit K, Al Ali HK, Jäkel N, Niederweise D (2013) Lenolidamide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO #077. Br J Haematol 162:202–209
17. Lentzsch S, O’Sullivan A, Kennedy RC, Abbas M, Dai L, Lalo Pregia S, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA (2012) Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 119:4608–4613
18. Pönisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D, East German Study Group of Haematology and Oncology (OSHO) (2008) Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol 143(2):191–200
19. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S (2011) Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 155:632–634
20. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485–1493
21. Palumbo A, Rajkumar SV, Dimopoulos MA, International Myeloma Working Group et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423, Epub 2007 Dec 20
22. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, on behalf of the International Myeloma Working group (2006) International uniform criteria for multiple myeloma. Leukemia 20:1467–1473
23. Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K (2010) Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park) 24(3 suppl 2):22–29
24. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternal L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lance Oncol 14:1055–1066
25. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart KA, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817–2825
26. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122:2331–2337
27. Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R (2010) Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 15(1):13–19
28. Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, Ali HA, Niederwieser D (2013) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139(3):499–508
29. Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Canc J 3:e162
30. Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Fitoussi O, Chaleteix C, Casassus P, Lenain P, Moreau P, Petillon MO, Mathiot C, Avet-Loiseau H (2013) Bendamustine, bortezomib and dexamethasone (BVD) in elderly patients with multiple myeloma in first relapse: final analysis of the Intergroupe Francophone Du Myelome (IFM) 2009–01 Trial. Blood (ASH Annual Meeting Abstracts), 653, Abstract 4044